Bo Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bo Zheng has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Hongyang Wang
National Center for Liver Cancer, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China
9 shared publications Jianmin Wu
9 shared publications- Kaiting Wang
Department of Medicine, Henan Medical College
9 shared publications - Lei Chen
Shanghai United Imaging Intelligence Co., Ltd., Shanghai, 200232, People’s Republic of China
9 shared publications - Rui Wu
Harbin Institute of Technology, Harbin, China
9 shared publications - Seogsong Jeong
Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Republic of Korea
9 shared publications
Latest Publications
- 4 March 2026
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 104, 66-73
Use of standardized order sets and associated outcomes in the Emergency Department: A scoping review
- 4 March 2026
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 104, 66-73
Use of standardized order sets and associated outcomes in the Emergency Department: A scoping review
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
N6-methyladenosine (m6A) has been reported as an important mechanism of posttranscriptional regulation. Programmed death-ligand 1 (PD-L1) is a primary immune inhibitory molecule expressed on tumor cells that promotes immune evasion. Here we report ALKBH5 as an important m6A demethylase that orchestrates PD-L1 expression in intrahepatic cholangiocarcinoma (ICC). Regulation of PD-L1 expression by ALKBH5 was confirmed in human ICC cell lines. Sequencing of the m6A methylome identified PD-L1 mRNA as a direct target of m6A modification whose levels were regulated by ALKBH5. Furthermore, ALKBH5 and PD-L1 mRNA were shown to interact. ALKBH5 deficiency enriched m6A modification in the 3′UTR region of PD-L1 mRNA, thereby promoting its degradation in a YTHDF2-dependent manner. In vitro and in vivo, tumor-intrinsic ALKBH5 inhibited the expansion and cytotoxicity of T cells by sustaining tumor cell PD-L1 expression. The ALKBH5-PD-L1–regulating axis was further confirmed in human ICC specimens. Single-cell mass cytometry analysis unveiled a complex role of ALKBH5 in the tumor immune microenvironment by promoting the expression of PD-L1 on monocytes/macrophages and decreasing the infiltration of myeloid-derived suppressor-like cells. Analysis of specimens from patients receiving anti-PD1 immunotherapy suggested that tumors with strong nuclear expression patterns of ALKBH5 are more sensitive to anti-PD1 immunotherapy. Collectively, these results describe a new regulatory mechanism of PD-L1 by mRNA epigenetic modification by ALKBH5 and the potential role of ALKBH5 in immunotherapy response, which might provide insights for cancer immunotherapies.Significance:This study identifies PD-L1 mRNA as a target of ALKBH5 and reveals a role for ALKBH5 in regulating the tumor immune microenvironment and immunotherapy efficacy.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
N6-methyladenosine (m6A) has been reported as an important mechanism of posttranscriptional regulation. Programmed death-ligand 1 (PD-L1) is a primary immune inhibitory molecule expressed on tumor cells that promotes immune evasion. Here we report ALKBH5 as an important m6A demethylase that orchestrates PD-L1 expression in intrahepatic cholangiocarcinoma (ICC). Regulation of PD-L1 expression by ALKBH5 was confirmed in human ICC cell lines. Sequencing of the m6A methylome identified PD-L1 mRNA as a direct target of m6A modification whose levels were regulated by ALKBH5. Furthermore, ALKBH5 and PD-L1 mRNA were shown to interact. ALKBH5 deficiency enriched m6A modification in the 3′UTR region of PD-L1 mRNA, thereby promoting its degradation in a YTHDF2-dependent manner. In vitro and in vivo, tumor-intrinsic ALKBH5 inhibited the expansion and cytotoxicity of T cells by sustaining tumor cell PD-L1 expression. The ALKBH5-PD-L1–regulating axis was further confirmed in human ICC specimens. Single-cell mass cytometry analysis unveiled a complex role of ALKBH5 in the tumor immune microenvironment by promoting the expression of PD-L1 on monocytes/macrophages and decreasing the infiltration of myeloid-derived suppressor-like cells. Analysis of specimens from patients receiving anti-PD1 immunotherapy suggested that tumors with strong nuclear expression patterns of ALKBH5 are more sensitive to anti-PD1 immunotherapy. Collectively, these results describe a new regulatory mechanism of PD-L1 by mRNA epigenetic modification by ALKBH5 and the potential role of ALKBH5 in immunotherapy response, which might provide insights for cancer immunotherapies.Significance:This study identifies PD-L1 mRNA as a target of ALKBH5 and reveals a role for ALKBH5 in regulating the tumor immune microenvironment and immunotherapy efficacy.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5-11 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S5. RNA-seq: Significant DEGs (differentially expressed genes) with log|foldchange| > 1 and p-value <0.05. Supplementary Table S6. m6A-seq: RBE- shALKBH5 peaks related genes. Supplementary Table S7. m6A-seq: RBE- shCtrl peaks related genes. Supplementary Table S8. m6A-seq: RBE-shALKBH5 unique peaks related genes. Supplementary Table S9. m6A-seq: RBE-shCtrl unique peaks related genes. Supplementary Table S10. m6A-seq: common differential peaks related genes Supplementary Table S11. RNA-seq: log2normalized_count.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5-11 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S5. RNA-seq: Significant DEGs (differentially expressed genes) with log|foldchange| > 1 and p-value <0.05. Supplementary Table S6. m6A-seq: RBE- shALKBH5 peaks related genes. Supplementary Table S7. m6A-seq: RBE- shCtrl peaks related genes. Supplementary Table S8. m6A-seq: RBE-shALKBH5 unique peaks related genes. Supplementary Table S9. m6A-seq: RBE-shCtrl unique peaks related genes. Supplementary Table S10. m6A-seq: common differential peaks related genes Supplementary Table S11. RNA-seq: log2normalized_count.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Materials and Methods
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Materials and Methods
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1-13 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Fig. S1. PD-L1 was regulated by ALKBH5 independent on FTO, METTL3 or METTL14. Supplementary Fig. S2. m6A-seq and mRNA-seq of RBE-shCtrl/shALKBH5 cells. Supplementary Fig. S3. Transient ALKBH5 and its mutant H204A overexpression increased the endogenous ALKBH5 protein level. Supplementary Fig. S4. ALKBH5 deficiency accelerates the degradation of PD-L1 mRNA dependent on YTHDF2. Supplementary Fig. S5. The role of YTHDF2 in regulating PD-L1 expression. Supplementary Fig. S6. Tumor cell intrinsic ALKBH5 facilitates tumor resistance to anti-tumor T cell immunity. Supplementary Fig. S7. T cell expansion was inhibited by tumor-intrinsic ALKBH5. Supplementary Fig. S8. The role of ALKBH5 in the proliferation and migration of ICC cell in vitro. Supplementary Fig. S9. PD-L1 is essential for ALKBH5-regulated anti-tumor T cell immunity. Supplementary Fig. S10. The correlation between ALKBH5 and PD-L1 transcripts in TCGA datasets. Supplementary Fig. S11. ALKBH5 positively correlates with PD-L1 expression in clinical ICC specimens. Supplementary Fig. S12. The role of ALKBH5 in ICC immune microenvironment. Supplementary Fig. S13. ALKBH5 deficiency in ICC cells relates to immunosuppressive microenvironment.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1-13 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Fig. S1. PD-L1 was regulated by ALKBH5 independent on FTO, METTL3 or METTL14. Supplementary Fig. S2. m6A-seq and mRNA-seq of RBE-shCtrl/shALKBH5 cells. Supplementary Fig. S3. Transient ALKBH5 and its mutant H204A overexpression increased the endogenous ALKBH5 protein level. Supplementary Fig. S4. ALKBH5 deficiency accelerates the degradation of PD-L1 mRNA dependent on YTHDF2. Supplementary Fig. S5. The role of YTHDF2 in regulating PD-L1 expression. Supplementary Fig. S6. Tumor cell intrinsic ALKBH5 facilitates tumor resistance to anti-tumor T cell immunity. Supplementary Fig. S7. T cell expansion was inhibited by tumor-intrinsic ALKBH5. Supplementary Fig. S8. The role of ALKBH5 in the proliferation and migration of ICC cell in vitro. Supplementary Fig. S9. PD-L1 is essential for ALKBH5-regulated anti-tumor T cell immunity. Supplementary Fig. S10. The correlation between ALKBH5 and PD-L1 transcripts in TCGA datasets. Supplementary Fig. S11. ALKBH5 positively correlates with PD-L1 expression in clinical ICC specimens. Supplementary Fig. S12. The role of ALKBH5 in ICC immune microenvironment. Supplementary Fig. S13. ALKBH5 deficiency in ICC cells relates to immunosuppressive microenvironment.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1-4 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S1. Clinical characteristics of 84 ICC patients depending on ALKBH5 expression levels. Supplementary Table S2. Clinical characteristics of 6 ICC specimens receiving immunotherapy. Supplementary Table S3: m6A-seq identified m6A peaks on PD-L1 mRNA. m6A peaks on PD-L1 mRNA and its corresponding primers for quantitative RT-PCR. Supplementary Table S4. m6A peaks in PD-L1 mRNA in m6A-Seq data from GSE87515.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1-4 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S1. Clinical characteristics of 84 ICC patients depending on ALKBH5 expression levels. Supplementary Table S2. Clinical characteristics of 6 ICC specimens receiving immunotherapy. Supplementary Table S3: m6A-seq identified m6A peaks on PD-L1 mRNA. m6A peaks on PD-L1 mRNA and its corresponding primers for quantitative RT-PCR. Supplementary Table S4. m6A peaks in PD-L1 mRNA in m6A-Seq data from GSE87515.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1-4 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S1. Clinical characteristics of 84 ICC patients depending on ALKBH5 expression levels. Supplementary Table S2. Clinical characteristics of 6 ICC specimens receiving immunotherapy. Supplementary Table S3: m6A-seq identified m6A peaks on PD-L1 mRNA. m6A peaks on PD-L1 mRNA and its corresponding primers for quantitative RT-PCR. Supplementary Table S4. m6A peaks in PD-L1 mRNA in m6A-Seq data from GSE87515.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1-4 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S1. Clinical characteristics of 84 ICC patients depending on ALKBH5 expression levels. Supplementary Table S2. Clinical characteristics of 6 ICC specimens receiving immunotherapy. Supplementary Table S3: m6A-seq identified m6A peaks on PD-L1 mRNA. m6A peaks on PD-L1 mRNA and its corresponding primers for quantitative RT-PCR. Supplementary Table S4. m6A peaks in PD-L1 mRNA in m6A-Seq data from GSE87515.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1-13 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Fig. S1. PD-L1 was regulated by ALKBH5 independent on FTO, METTL3 or METTL14. Supplementary Fig. S2. m6A-seq and mRNA-seq of RBE-shCtrl/shALKBH5 cells. Supplementary Fig. S3. Transient ALKBH5 and its mutant H204A overexpression increased the endogenous ALKBH5 protein level. Supplementary Fig. S4. ALKBH5 deficiency accelerates the degradation of PD-L1 mRNA dependent on YTHDF2. Supplementary Fig. S5. The role of YTHDF2 in regulating PD-L1 expression. Supplementary Fig. S6. Tumor cell intrinsic ALKBH5 facilitates tumor resistance to anti-tumor T cell immunity. Supplementary Fig. S7. T cell expansion was inhibited by tumor-intrinsic ALKBH5. Supplementary Fig. S8. The role of ALKBH5 in the proliferation and migration of ICC cell in vitro. Supplementary Fig. S9. PD-L1 is essential for ALKBH5-regulated anti-tumor T cell immunity. Supplementary Fig. S10. The correlation between ALKBH5 and PD-L1 transcripts in TCGA datasets. Supplementary Fig. S11. ALKBH5 positively correlates with PD-L1 expression in clinical ICC specimens. Supplementary Fig. S12. The role of ALKBH5 in ICC immune microenvironment. Supplementary Fig. S13. ALKBH5 deficiency in ICC cells relates to immunosuppressive microenvironment.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1-13 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Fig. S1. PD-L1 was regulated by ALKBH5 independent on FTO, METTL3 or METTL14. Supplementary Fig. S2. m6A-seq and mRNA-seq of RBE-shCtrl/shALKBH5 cells. Supplementary Fig. S3. Transient ALKBH5 and its mutant H204A overexpression increased the endogenous ALKBH5 protein level. Supplementary Fig. S4. ALKBH5 deficiency accelerates the degradation of PD-L1 mRNA dependent on YTHDF2. Supplementary Fig. S5. The role of YTHDF2 in regulating PD-L1 expression. Supplementary Fig. S6. Tumor cell intrinsic ALKBH5 facilitates tumor resistance to anti-tumor T cell immunity. Supplementary Fig. S7. T cell expansion was inhibited by tumor-intrinsic ALKBH5. Supplementary Fig. S8. The role of ALKBH5 in the proliferation and migration of ICC cell in vitro. Supplementary Fig. S9. PD-L1 is essential for ALKBH5-regulated anti-tumor T cell immunity. Supplementary Fig. S10. The correlation between ALKBH5 and PD-L1 transcripts in TCGA datasets. Supplementary Fig. S11. ALKBH5 positively correlates with PD-L1 expression in clinical ICC specimens. Supplementary Fig. S12. The role of ALKBH5 in ICC immune microenvironment. Supplementary Fig. S13. ALKBH5 deficiency in ICC cells relates to immunosuppressive microenvironment.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5-11 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S5. RNA-seq: Significant DEGs (differentially expressed genes) with log|foldchange| > 1 and p-value <0.05. Supplementary Table S6. m6A-seq: RBE- shALKBH5 peaks related genes. Supplementary Table S7. m6A-seq: RBE- shCtrl peaks related genes. Supplementary Table S8. m6A-seq: RBE-shALKBH5 unique peaks related genes. Supplementary Table S9. m6A-seq: RBE-shCtrl unique peaks related genes. Supplementary Table S10. m6A-seq: common differential peaks related genes Supplementary Table S11. RNA-seq: log2normalized_count.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5-11 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Table S5. RNA-seq: Significant DEGs (differentially expressed genes) with log|foldchange| > 1 and p-value <0.05. Supplementary Table S6. m6A-seq: RBE- shALKBH5 peaks related genes. Supplementary Table S7. m6A-seq: RBE- shCtrl peaks related genes. Supplementary Table S8. m6A-seq: RBE-shALKBH5 unique peaks related genes. Supplementary Table S9. m6A-seq: RBE-shCtrl unique peaks related genes. Supplementary Table S10. m6A-seq: common differential peaks related genes Supplementary Table S11. RNA-seq: log2normalized_count.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Materials and Methods
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Supplementary Materials and Methods